Christine L. Phillips, MD

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel. Appell, LE; Baggott, C; Nguyen, K; Prabhu, S; Pacenta, H; John, S; Fabrizio, VA; Phillips, CL; Rossoff, J; Talano, J-A; Mackall, CL; Laetsch, TW; Mcnerney, K; Schultz, LM. Blood advances. 2026; 10(1):106-110.

Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report. Rangarajan, HG; Chellapandian, D; Atshan, R; Ahn, KW; Kumar, S; Knight, TE; Leung, W; Ganguly, S; Williams, KM; Shah, NN; Qayed, M; Sharma, A; Broglie, L; Satwani, P. Transplantation and Cellular Therapy. 2025.

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. John, S; Curran, KJ; Hall, EM; Keating, AK; Baumeister, SHC; Nikiforow, S; Driscoll, T; Moskop, A; Mcnerney, KO; Phillips, CL; Ramos, R; Krueger, J; Guest, E; Grupp, SA. Blood advances. 2025; 9(20):5249-5262.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Naik, S; Selukar, S; Talleur, AC; Deshpande, S; Llaurador Caraballo, G; Fabrizio, VA; Rouce, RH; Zeng, XL; Vatsayan, A; Rossoff, J; Nguyen, KP; Baggott, C; Schultz, LM; Mcnerney, KO. Blood advances. 2025; 9(19):5070-5084.

Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. Frigault, MJ; Maziarz, RT; Park, JH; Lazaryan, A; Shah, NN; Svoboda, J; Lekakis, L; Reshef, R; Phillips, CL; Burke, L; Lei, J; Pratta, M; Morariu-Zamfir, R; Dipersio, JF. Blood. 2025; 146(4):422-436.

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Lust, H; Schultz, LM; Kwon, S; Roloff, GW; Aldoss, I; Baggott, C; John, S; Rossoff, JE; Mcnerney, KO; Fabrizio, VA; Sutherland, KC; Shah, BD; Muffly, L; Faramand, R. Blood advances. 2025; 9(11):2763-2772.

Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation. Sharma, A; O'brien, MM; Phillips, CL; Schultz, KR; Mehta, PA; Kebriaei, P; Vandendries, E; Dorman, S; Jiang, W; Zhang, F; Asomaning, K; Zhang, M-J; De Lima, MJG; Marks, DI; Saber, W. Journal of Clinical Oncology. 2025; 43(16_suppl).

Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Analysis of the Effect of Current Tisagenlecleucel (tisa-cel) Manufacturing in Pediatric and Young Adult Patients (pts) with ALL. Rouce, RH; Dolan, JG; Phillips, CL; Qayed, M; Pulsipher, MA; Vernau, LM; Galletta, TJ; Votaw, S; Caraballo, GL; Yang, H; Tesfaye, M; Lee, S; O'sullivan, E; Grupp, SA. Transplantation and Cellular Therapy. 2025; 31(2):s219.

Impact of Graft Versus Host Disease Following Allogeneic Hematopoietic Cell Transplantation on Leukemia Free Survival in Hematologic Malignancies: A CIBMTR Analysis. Bauchat, A; Peterson, A; Ahn, KW; Mehta, PA; Phillips, CL; Schultz, KR; Sharma, A; Broglie, L; Qayed, M. Transplantation and Cellular Therapy. 2025; 31(2):s60-s61.

Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion. Appell, L; Modi, A; Baggott, C; Nguyen, K; Prabhu, S; Pacenta, HL; Fabrizio, VA; Phillips, CL; Rossoff, J; Stefanski, HE; John, S; Laetsch, TW; Mcnerney, KO; Schultz, L. Transplantation and Cellular Therapy. 2025; 31(2):s230-s231.